VYGRVoyager Therapeutics, Inc.同业对比
Voyager Therapeutics, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VYGR本股 | $186M#9 | — | 1.2x#1 | 4.6x#4 | -49.5%#4 | -84.2%#12 | -326.6%#5 | -77.6%#8 | — | — | -29.2%#9 | — |
| TARA | $219M#3 | — | 1.4x#3 | 74.2x#9 | — | -28.7%#10 | -2189.6%#9 | -35.6%#5 | — | — | 21.3%#6 | — |
| PLX | $217M#4 | 11.7x#1 | 3.0x#6 | 4.1x#1 | -1.2%#3 | -325.2%#14 | -10.4%#1 | -9.2%#3 | -12.3%#1 | 3#1 | 46.2%#2 | — |
| IVVD | $221M#2 | — | 1.2x#2 | 4.1x#2 | 110.5%#1 | 69.1%#3 | -104.0%#2 | -29.0%#4 | — | — | -35.2%#11 | — |
| AVXL | $226M#1 | — | 2.0x#4 | — | — | -7.8%#7 | — | -41.2%#7 | — | — | -72.3%#16 | — |
| ALEC | $208M#5 | — | — | 9.9x#6 | -79.1%#7 | -20.2%#9 | -741.3%#7 | — | — | — | -36.7%#12 | — |
| SRZN | $200M#6 | — | — | 57.6x#8 | -67.4%#6 | -280.8%#13 | -1210.6%#8 | — | — | — | 43.8%#3 | — |
| ACOG | $191M#8 | — | 3.6x#10 | 18.7x#7 | — | -39.8%#11 | -221.7%#4 | -39.0%#6 | — | — | 5.0%#7 | — |
| CHRS | $193M#7 | — | 3.2x#7 | 4.6x#3 | 59.8%#2 | 489.4%#1 | -429.5%#6 | 276.2%#2 | -351.2%#3 | — | -7.7%#8 | — |
| ABOS | $186M#10 | — | 3.3x#9 | — | — | -18.6%#8 | — | -211.9%#12 | -421.4%#4 | — | 104.4%#1 | — |
| DTIL | $178M#11 | — | 3.9x#11 | 5.2x#5 | -50.1%#5 | -738.0%#15 | -152.2%#3 | -101.0%#9 | — | — | 41.2%#5 | — |
| OTLK | $167M#12 | — | — | 118.0x#11 | — | 17.2%#5 | -4744.3%#10 | — | -12.8%#2 | — | -33.5%#10 | — |
| HUMA | $158M#13 | — | 5.1x#12 | 77.6x#10 | — | 72.5%#2 | -5306.0%#11 | -130.6%#11 | — | — | -62.8%#15 | — |
| ARMP | $155M#14 | — | — | — | — | -818.8%#16 | — | — | — | — | 41.5%#4 | 0.1%#1 |
| TNYA | $152M#15 | — | 2.2x#5 | — | — | 18.5%#4 | — | -130.5%#10 | — | — | -44.6%#13 | — |
| NMRA | $145M#16 | — | 3.2x#8 | — | — | -2.8%#6 | — | 532.2%#1 | -594.0%#5 | — | -46.2%#14 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议